A new lacrimal duct repair stent composited with degradable bio-amniotic membrane

Abstract

The invention discloses a novel degradable biological amniotic membrane composite lacrimal passage repair stent which comprises a stent body. The stent body comprises a composite inner core and an amniotic membrane tegment; the amniotic membrane tegment is wound on the composite inner core to form at least one pointed end; the composite inner core is formed by twisting at least one strand of amniotic membrane core and at least one strand of medical suture; one end of one strand of medical suture penetrates out of the pointed end. The novel degradable biological amniotic membrane composite lacrimal passage repair stent solves the key problem of smooth healing of a lacrimal ductule, has the effects of promoting repairing and healing of the mucous epithelium of a lacrimal passage, reducing scars, reducing inflammation and preventing re-adhesion, enables biological activity of the amniotic membrane to be kept and prolonged, can meet the requirement of clinical application for degrading time, enables a normal anatomy function of the lacrimal ductule to be recovered, does not need external force for extirpation and cannot cause secondary damage.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to a novel lacrimal duct repair bracket composed of degradable bio-amnion. Background technique [0002] Lacrimal duct obstruction diseases (LDOD) refer to a group of diseases caused by various reasons, with lacrimal duct obstruction as the pathological feature and epiphora as the main clinical manifestation. It is a common and frequently-occurring disease in ophthalmology. Cystic anastomosis and probing of the punctum lacrimal duct. Simple dredging, if there is no support to keep the lacrimal duct lumen expanded after lacrimal duct laser and high-frequency electrotherapy, the postoperative wound surface is not completely cured due to reactive edema or original chronic inflammation, and the lacrimal duct lumen is easily closed. Adhesion of the cavity wall, followed by tissue repair wound adhesion and healing, resulting in reocclusion of the lacrimal duct lumen. Lacrimal duct s...

AI Technical Summary

Problems solved by technology

The implantation of the silicone tube stent can support the stoma, and at the same time drain the blood and secretions in the lacrimal sac, reduce inflammation, and accelerate wound healing. Damage to the lacrimal duct tissue, and even secondary blockage of the lacrimal duct due to adhesion with the lacrimal duct

[0006] The Chinese patent application number 200720005808.4 discloses a probing and drainage tube for the lacrimal duct. This design enables the product to support the lacrimal duct and also has the functions of washing and administering drugs, but the product itself does not have the function of repairing. function, and the tube body needs to be pulled out, which is easy to cause secondary damage

[0007] The first-generation amniotic lacrimal duct repair stent developed by Jiangxi Ruiji Bioengineering Technology Co., Ltd. can adapt to the tortuous structure of the lacrimal duct, avoiding damage to the lacrimal duct tissue caused by pulling friction and secondary blockage caused by adhesion. , due to the special function of the amniotic membrane has a good therapeutic effect on diseased tissue, has the advantages of promoting the recovery of lacrimal duct epithelial function, preventing scar formation, good long-term effect, low recurrence rate, and self-degradation. There is a problem that the degradation rate is too fast, which affects the therapeutic effect

Images